ArticleFrontiers in oncology2025
Study on the value of gastrin 17 and aldehyde dehydrogenase 1 in gastric juice for early diagnosis in gastric cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biomarkers in Gastric Cancer: Blood Biomarkers, Liquid Biopsy, Artificial Intelligence, and Risk-Stratified Care.Cancers · 2026Review
- Serology and magnetically controlled capsule gastroscopy for opportunistic screening of high-risk events in gastric cancer development: a cross-sectional study.Frontiers in medicine · 2026Article
- Diagnostic value of serum pepsinogen, gastrin, and carbohydrate antigens in gastric ulcer and gastric cancer.World journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the diagnostic utility of aldehyde dehydrogenase 1 (ALDH1) and gastrin 17 (G-17) levels in the gastric juice of patients with gastric cancer and to track changes in the levels of these markers in the gastric juice of these patients. Methods: 126 individuals were diagnosed via gastroscopy. This trial includes gastric mucosal histology and gastroscopy performed at Hefei Second People's Hospital between March 2023 and March 2024. On the basis of the results of gastroscopy and gastric mucosal histology, all the participants were categorized into three groups: 30 patients with gastric cancer (GC), 34 patients with gastric ulcer (GU) and 62 patients with gastritis. Thirty patients with chronic nonatrophic gastritis were chosen from the physical examination center, and thirty-two patients with chronic atrophic gastritis (CAG) composed the gastritis group. As the control group, they were chosen at the physical testing center. An enzyme-related immunosorbent assay (ELISA) was used to quantify the levels of G-17 and ALDH1 in each group. A correlation study was performed on the levels of ALDH1 and G-17 in the gastric juice. By using binomial logistic regression analysis, the impact of G-17 and ALDH1 in gastric juice on the incidence of gastric cancer was examined. To illustrate the predictive usefulness of G-17 and ALDH1 in gastric juice for GC diagnosis, a receiver operating characteristic (ROC) curve was generated. Results: The gastric juice of the gastric cancer group had higher levels of ALDH1 and G-17 than did the gastric juice of the gastritis group and GU group ( Conclusion: The development of gastric cancer is influenced by increased levels of ALDH1 and G-17 in gastric juice. The diagnosis of gastric cancer may be made more accurately by combining the two gastric fluid markers, which can be found in gastric juice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.